使TACEHCC (CHANCE2204)

Zhi-Cheng Jin1,2, Jingwei Wei3, Yu-Dong Xiao1,4

  • 1Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.

Hepatology (Baltimore, Md.)
|November 10, 2025
PubMed
概括

结合全球和内异质性的新型成像生物标志物预测了接受跨动脉化血栓化,免疫检查点抑制剂和分子向治疗 (TACE-ICI-MTT) 的肝细胞癌 (HCC) 患者的治疗反应和生存率. 这种生物标志物也反映了瘤.